|ZIOPHARM Oncology, Inc.|
United States - Map
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the discovery and development of cancer therapies that address unmet medical needs through synthetic biology. The company is employing novel gene expression and control technology to deliver DNA for the treatment of cancer. Its technology platform employs Intrexon Corporations RheoSwitch Therapeutic System platform to turn on and off, and modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is being evaluated in Phase II clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The company is also developing novel small molecules as potential cancer therapeutics. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
|ZIOPHARM Oncology, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 6. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 2; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Jonathan J. Lewis M.D., Ph.D.,
Chief Exec. Officer and Director
|Mr. Caesar J. Belbel ,
Chief Legal Officer, Exec. VP, Principal Scientific, Regulatory, & Medical Advisors and Sec.
|Dr. Hagop Youssoufian Ph.D., M.Sc.,M.D.,
Pres of R&D and Chief Medical Officer
|Mr. Richard E. Bagley ,
|Mr. Kevin G. Lafond ,
Chief Financial Officer, Chief Accounting Officer, VP, Treasurer and Corp. Controller
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|